Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · February 28, 2024

Overall Survival Outcomes of Patients With Advanced EGFR-Mutant NSCLC Receiving Osimertinib vs Gefitinib Followed by Osimertinib

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
J. Clin. Oncol 2024 Feb 07;[EPub Ahead of Print], J Remon, B Besse, SP Aix, A Callejo, K Al-Rabi, R Bernabe, L Greillier, M Majem, N Reguart, I Monnet, S Cousin, P Garrido, G Robinet, RG Campelo, A Madroszyk, J Mazières, H Curcio, B Wasąg, Y Pretzenbacher, F Grillet, AC Dingemans, R Dziadziuszko

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading